ATE382333T1 - Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen - Google Patents

Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen

Info

Publication number
ATE382333T1
ATE382333T1 AT01921262T AT01921262T ATE382333T1 AT E382333 T1 ATE382333 T1 AT E382333T1 AT 01921262 T AT01921262 T AT 01921262T AT 01921262 T AT01921262 T AT 01921262T AT E382333 T1 ATE382333 T1 AT E382333T1
Authority
AT
Austria
Prior art keywords
lipide
drug delivery
delivery systems
based drug
parasitic infections
Prior art date
Application number
AT01921262T
Other languages
English (en)
Inventor
Kent Jorgensen
Jesper Davidsen
Charlotte Vermehren
Sven Frokjaer
Ole Mouritsen
Original Assignee
Liplasome Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma As filed Critical Liplasome Pharma As
Application granted granted Critical
Publication of ATE382333T1 publication Critical patent/ATE382333T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Cosmetics (AREA)
AT01921262T 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen ATE382333T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200000616 2000-04-12

Publications (1)

Publication Number Publication Date
ATE382333T1 true ATE382333T1 (de) 2008-01-15

Family

ID=8159422

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01921263T ATE336267T1 (de) 2000-04-12 2001-04-11 Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
AT01921262T ATE382333T1 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01921263T ATE336267T1 (de) 2000-04-12 2001-04-11 Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe

Country Status (11)

Country Link
US (4) US7368254B2 (de)
EP (3) EP1272161B1 (de)
JP (3) JP2003530338A (de)
AT (2) ATE336267T1 (de)
AU (3) AU2001248303A1 (de)
CY (2) CY1105792T1 (de)
DE (3) DE60122304T2 (de)
DK (3) DK1272160T3 (de)
ES (3) ES2280355T3 (de)
PT (3) PT1272160E (de)
WO (3) WO2001076556A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2002085391A1 (es) * 2001-04-24 2002-10-31 Luis Alberto Costa Uso de una fosfolipasa a2 para la preparacion de composiciones farmaceuticas y/o cosmeticas para la prevencion y/o el tratamiento local y/o sistemico de enfermedades y/o procesos provocados por patogenos intra y extracelulares que expresen fosfolipidos de membrana
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2338525A3 (de) * 2003-07-09 2011-08-03 California Pacific Medical Center Fernerkennung von Substanzabgabe an Zellen
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
US20080113014A1 (en) * 2004-01-28 2008-05-15 Ltt Bio-Pharma Co., Ltd. Method for Screening for Compounds Safe for Gastric Mucosa
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
EP1933809B1 (de) * 2005-10-11 2012-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zusammensetzungen für die nasale abgabe
US7998945B2 (en) * 2005-12-23 2011-08-16 Jado Technologies Gmbh Methods for the treatment and amelioration of atopic dermatitis
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
WO2011022707A1 (en) 2009-08-21 2011-02-24 Henk-Andre Kroon Vesicular formulations
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
JP2015509507A (ja) * 2012-03-09 2015-03-30 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 内臓リーシュマニア症を治療するための従来型リポソームと長期循環型リポソームを含有する医薬組成物
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US20140079773A1 (en) * 2012-09-18 2014-03-20 Comfort Care For Animals Llc Encapsulating liposomes
HRP20211669T1 (hr) 2015-06-30 2022-02-18 Sequessome Technology Holdings Limited Multifazni pripravci
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
FR2638639A1 (fr) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (ja) 1989-08-04 1991-03-26 Toshiba Corp 電動機制御装置
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Also Published As

Publication number Publication date
DE60132184T2 (de) 2009-01-15
WO2001076555A3 (en) 2002-03-14
WO2001076644A2 (en) 2001-10-18
CY1105792T1 (el) 2011-02-02
PT1272160E (pt) 2007-04-30
US20030175205A1 (en) 2003-09-18
CY1106462T1 (el) 2012-01-25
DK1272225T3 (da) 2006-12-27
US7166297B2 (en) 2007-01-23
JP2003530339A (ja) 2003-10-14
DE60126072T2 (de) 2007-11-08
AU2001248301A1 (en) 2001-10-23
DE60122304T2 (de) 2007-08-09
ES2280355T3 (es) 2007-09-16
PT1272225E (pt) 2007-01-31
DK1272160T3 (da) 2007-05-21
WO2001076555A2 (en) 2001-10-18
DE60132184D1 (de) 2008-02-14
ES2295149T3 (es) 2008-04-16
US20030170297A1 (en) 2003-09-11
EP1272160B1 (de) 2007-01-17
DE60122304D1 (de) 2006-09-28
DE60126072D1 (de) 2007-03-08
EP1272225B1 (de) 2006-08-16
WO2001076556A2 (en) 2001-10-18
PT1272161E (pt) 2008-02-08
EP1272225A2 (de) 2003-01-08
WO2001076644A3 (en) 2002-03-14
AU2001248302A1 (en) 2001-10-23
EP1272160A2 (de) 2003-01-08
US7368254B2 (en) 2008-05-06
JP2003530338A (ja) 2003-10-14
ATE336267T1 (de) 2006-09-15
EP1272161B1 (de) 2008-01-02
ES2270991T3 (es) 2007-04-16
AU2001248303A1 (en) 2001-10-23
US20030162748A1 (en) 2003-08-28
WO2001076556A3 (en) 2002-07-11
US20070134153A1 (en) 2007-06-14
EP1272161A2 (de) 2003-01-08
JP2003530362A (ja) 2003-10-14
DK1272161T3 (da) 2008-05-19

Similar Documents

Publication Publication Date Title
ATE382333T1 (de) Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
ATE336229T1 (de) Zusammensetzung auf der basis polymerer mizellen
NO20000573L (no) Kjemiske forbindelser
SE0300010D0 (sv) Novel Compounds
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ATE337019T1 (de) Geladene lipide und deren verwendung
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
ATE478141T1 (de) Durch phagendisplay identifizierte zielpeptide des menschen und der maus
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
CA2263203A1 (en) 3,6-ketal and enol ether macrolide antibiotics
ES2180274T3 (es) Disoluciones nasales.
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
DE60038252D1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
NO20004795D0 (no) Peptidbaserte forbindelser
BR0007514A (pt) Macrolìdeos com atividade anti-inflamatória
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
PA8553101A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
BR9911885A (pt) Inibidores da angiogênese
RS51420B (en) HYPERSTRUCTURE AMYLOPECTIN FOR USE IN THE PROCEDURES OF SURGICAL OR THERAPEUTIC TREATMENT OF mammals OR IN THE PROCEDURES OF DIAGNOSIS, AND PARTICULARLY FOR USE AS A PLASMA VOLUME EXPANDER
BR0011845A (pt) Complexo farmacêutico
DE60235549D1 (de) Pharmazeutische formulierung und darin enthaltende liganden; uea-1 mimetika
HUP0202888A2 (hu) Xenogén oligo- és/vagy poliribonukleotidokat tartalmazó gyógyszerkészítmény
DE60143020D1 (de) 9-alkylamino-1-nitroacridin-derivate
TUCKER Keep tabs on CA-MRSA infection by obtaining cultures

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272161

Country of ref document: EP

REN Ceased due to non-payment of the annual fee